Demystifying NT-proBNP as a Screening Marker for Underwriting Purposes
Since the early 2000s cardiac biomarkers have become the cornerstone for diagnosis, risk stratification and therapeutic decision in cardiovascular diseases, specifically NT-proBNP (congestive heart failure) and cardiac troponins (acute coronary syndromes).
ReFlections Medical Underwriting Newsletter Vol 35
Articles in the latest edition of RGA's ReFlections Newsletter include:
- Trends in Respiratory Diseases
- Biomarkers: Can They Add Value? Part 2
- Pediatric Underwriting
- What Does the Continuity of Care Documents Hold for Underwriters?